Dynamk Capital is the famous VC, which was founded in 2016. The venture was found in North America in United States. The leading representative office of defined VC is situated in the New York.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Dynamk Capital, startups are often financed by Ventry Industries, The Thiel Foundation, National Institutes of Health. The meaningful sponsors for the fund in investment in the same round are Vanedge Capital, Third Kind Venture Capital, SV Angel. In the next rounds fund is usually obtained by Vanedge Capital, National Institutes of Health, Madrona Venture Group.
The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Chemical, Biotechnology. Among the various public portfolio startups of the fund, we may underline Envisagenics, Flodesign Sonics, RoosterBio
The increased amount of exits for fund were in 2019. The important activity for fund was in 2019. Comparing to the other companies, this Dynamk Capital performs on 9 percentage points less the average number of lead investments. Deals in the range of 5 - 10 millions dollars are the general things for fund. The real fund results show that this VC is 80 percentage points more often commits exit comparing to other companies. The fund is constantly included in less than 2 deals per year.
The fund was created by Daniella Kranjac. We also calculated 3 valuable employees in our database.
Funds with similar focus
Fund Name | Location |
AGTech Holdings | China, Hong Kong, Hong Kong Island |
BPI Capital Partners | New York, New York, United States |
Brockhaus Private Equity | Frankfurt, Germany, Hessen |
Curious Office Partners | Seattle, United States, Washington |
Enphase Energy | California, Petaluma, United States |
Ernst & Young | England, London, United Kingdom |
K-Svets Venture | Sweden, Vastra Gotaland, Västra Götaland County |
Knoll Capital Management | - |
Launch Africa | Ebène, Mauritius, Plaines Wilhems |
Leerink Transformation Partners | Boston, Massachusetts, United States |
Linden Capital | Berlin, Berlin, Germany |
MESA | New York, New York, United States |
O2h Ventures | - |
REAL WORLD | Japan, Kanagawa Prefecture, Kawasaki |
Riverbed Technology | California, San Francisco, United States |
Sandler Capital | New York, New York, United States |
Shenzhen Aoto Electronics | China, Guangdong, Tianjin |
SSC Fund | Beijing, Beijing, China |
Toyota Tunas | - |
UCAL Fuel Systems | Chennai, India, Tamil Nadu |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
CellFE | $22M | 27 Sep 2023 | California, United States | ||
Lucid Scientific | $7M | 05 Sep 2023 | Atlanta, Georgia, United States | ||
Vernal Biosciences | $20M | 27 Jun 2023 | Burlington, Vermont, United States | ||
Vernal Biosciences | $21M | 02 Jun 2022 | Burlington, Vermont, United States | ||
Bionter | $3M | 27 Apr 2022 | Riehen, Basel-Stadt, Switzerland | ||
Xcell Biosciences | $27M | 19 Jan 2022 | San Francisco, California, United States | ||
Curi Bio | $10M | 29 Dec 2021 | Seattle, Washington, United States | ||
Virica Biotech | 04 Oct 2021 | Ottawa, Ontario, Canada | |||
Envisagenics | $19M | 29 Sep 2021 | New York, New York, United States |
– Lightspeed Microscopy, a Seattle startup, raised $4m in a Series A financing round.
– The round was led by Dynamk Capital and joined by other investors.
– The company is developing an end-to-end microscopy system for pathologists.
– The platform adapts a type of microscopy commonly used for basic research to assess pathology specimens in three dimensions.
– Curi Bio Raises $6M Series A Financing Round for iPSC-derived Predictive Platforms
– The round was led by Dynamk Capital
– The investment will be used to scale its existing business and accelerate the development of new innovative human stem cell platforms, including its MantarrayTM platform.
– With this financing round, Curi Bio is welcoming Dr. Gustavo Mahler, Managing Partner at Dynamk Capital, as a new board member.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
CellFE | $22M | 27 Sep 2023 | California, United States | ||
Lucid Scientific | $7M | 05 Sep 2023 | Atlanta, Georgia, United States | ||
Vernal Biosciences | $20M | 27 Jun 2023 | Burlington, Vermont, United States | ||
Vernal Biosciences | $21M | 02 Jun 2022 | Burlington, Vermont, United States | ||
Bionter | $3M | 27 Apr 2022 | Riehen, Basel-Stadt, Switzerland | ||
Xcell Biosciences | $27M | 19 Jan 2022 | San Francisco, California, United States | ||
Curi Bio | $10M | 29 Dec 2021 | Seattle, Washington, United States | ||
Virica Biotech | 04 Oct 2021 | Ottawa, Ontario, Canada | |||
Envisagenics | $19M | 29 Sep 2021 | New York, New York, United States |